NVS Should I Buy
-
$
0.000
0.000(0.000%)
At close0.000(0.000%)Aft-market
ET
Novartis AG (NVS) is a good buy for a beginner investor with a long-term strategy and $50,000-$100,000 available for investment. The company's strong pipeline potential, recent acquisition to enhance its allergy portfolio, and positive analyst ratings outweigh the short-term technical weakness and financial performance concerns. The stock's current price presents an attractive entry point for long-term growth.
The MACD is negative (-1.106) and contracting, indicating bearish momentum. RSI is neutral at 39.852, suggesting no clear signal. Moving averages are converging, and the stock is trading near its pivot level of 150.561, with support at 146.489 and resistance at 154.633. Overall, the technical indicators suggest a neutral to slightly bearish short-term trend.
Acquisition of Excellergy for $2 billion to strengthen its allergy portfolio, expected to enhance long-term growth.
Positive analyst sentiment with multiple price target upgrades, including Morgan Stanley raising its target to $170 and BofA to $
Inclusion in the Vanguard International High Dividend ETF, highlighting its appeal as a high-dividend stock.
Recent financial performance shows a decline in net income (-14.51% YoY), EPS (-11.43% YoY), and gross margin (-1.48% YoY).
Neutral trading sentiment from hedge funds and insiders.
Short-term technical indicators suggest bearish momentum.
In Q4 2025, revenue increased by 2.23% YoY to $13.86 billion, but net income dropped by 14.51% YoY to $2.41 billion. EPS declined by 11.43% YoY to 1.24, and gross margin fell slightly to 74.44%. While revenue growth is positive, declining profitability metrics are a concern.
Analysts are generally positive on Novartis, with multiple firms raising price targets and maintaining Buy or Overweight ratings. Morgan Stanley sees $23B in risk-adjusted pipeline potential, and BofA highlights upgrades in key pipeline assets. However, Bernstein has a Market Perform rating, citing potential sales declines in the long term.
